ONE hundred years ago, the traditional world hitherto known to physicists ceased to exist. Within the time span of a generation, the foundations of classical mechanics were shattered by Einstein’s theory of relativity and quantum mechanics. A new era and the Golden Age of New Physics began. One hundred years later—today—a comparable revolution is taking place and this time in medicine. Yet, few practicing physicians inside and outside our specialty are aware of this revolution. When future historians will look back at the first decades of the 21st century, they may refer to this time period as the era of genomic medicine. An era where for the first time the full power and information of the human genome became accessible and was harnessed to improve the lives and conditions of everyday patients. Two reports in this issue of Anesthesiology1,2  represent a milestone for our specialty: for the first time exome sequencing has been used to identify novel mutations for malignant hyperthermia.

What Is Exome Sequencing and Why Is It Relevant for All of Us, Not Just Experts?

Exome sequencing is like the little brother of whole genome sequencing.3  For decades, a dream of geneticists, sequencing a whole human genome, has become a distinct possibility after the Human Genome Project was completed and a first draft released in the year 2000.4  At a cost of 3 billion dollars, with several hundreds of investigators involved and taking 10 yr of work to be completed, the Human Genome Project was without a doubt one of the most ambitious and costly biomedical research projects ever undertaken. Although many have questioned whether the investment in the Human Genome Project “was worth it” or “has paid off,” all scientific discoveries that jump-started the genomic medicine revolution in the last decade would have been impossible without the Human Genome Project, including exome sequencing. This is for two main reasons: first, the Human Genome Project provided a template of the human genome that all subsequently sequenced genomes could be compared with.5  Nowadays, geneticists can simply align the millions of little DNA pieces (“shotgun sequencing”) from a human genome on the backbone of a reference genome. Back then, the researchers in the Human Genome Project had to assemble these millions of DNA pieces in the right order first—a painstaking and arduous process (fig. 1). Second, and this is the most dramatic development, the Human Genome Project resulted in a huge technological race toward cheaper and faster sequencing. Outpacing Moore’s law, the law in the semiconductor field that states that the number of transistors on an integrated circuit doubles every 18 months, the cost of sequencing has decreased and the speed of sequencing has increased by several orders of magnitude. In the year 2013, the cost to sequence a whole human genome is approximately $5,000 (not including analysis) and can be accomplished in less than 2 weeks. Yet, despite this dramatic reduction in cost and time to sequence a genome, both are still prohibitive for everyday clinical purposes, not even including the time and effort for the nontrivial analysis of the genome data. This is where exome sequencing comes in.

Fig. 1.

“I think I found a corner piece!” Reprinted with permission from the cartoonist Drew Sheneman.

Fig. 1.

“I think I found a corner piece!” Reprinted with permission from the cartoonist Drew Sheneman.

While whole genome sequencing truly sequences the whole human genome with its 3 billion base pairs (typically in 40–50× coverage to remove sequencing errors), exome sequencing represents a smart, efficient, and cost-effective approach to identify potentially disease-causing mutations. A mammalian gene is broken up into two parts: exons and introns (fig. 2). Exons are the stretches of DNA that are made (transcribed and translated) into protein (“coding DNA”). The vast majority of disease-causing mutations are located in exons. Introns are not made into protein and typically do not harbor disease-causing mutations. All the exons of the human genome combined (“exome”) comprise only a small fraction of the human genome, approximately 1.5%. So instead of sequencing the whole genome (3 billion bases), one could just target and sequence the exome (40 million bases) and still have a reasonably high probability of being able to identify a disease-causing mutation. This smart and efficient approach, originally labeled “targeted exome capture and sequencing” and now simply referred to as exome sequencing, was first used by Jay Shendure lab at the University of Washington in Seattle.6  It was an instant landmark achievement first published in 2009 and has been cited more than 500 times since then. What is more important than the number of citations, however, is that the novel approach of exome sequencing has spearheaded a revolution in genomic medicine—and this brings us to the questions of relevance.

Fig. 2.

Schematic organization of a human (mammalian) gene: exons (black blocks) are the protein coding elements of the gene. Introns (white) are noncoding elements. All exons in the human genome comprise the exome.

Fig. 2.

Schematic organization of a human (mammalian) gene: exons (black blocks) are the protein coding elements of the gene. Introns (white) are noncoding elements. All exons in the human genome comprise the exome.

Why Is Exome Sequencing Relevant for More Than Just Experts?

Exome sequencing has become highly relevant and important in less than 5 yr since it was first introduced, because it makes genome sequencing attainable and useful in everyday clinical practice. Today, one can get an exome sequenced at a cost of less than $750 and in just 1 day, and this has made exome sequencing very attractive for many clinicians (at present mostly pediatricians and oncologists). It should be noted, however, that obtaining the exome data from sequencing requires 1 day, but not the analysis. The analysis of exome sequencing data is not trivial, requires an experienced bioinformatician, and often takes several weeks. Exome sequencing has resulted in some spectacular successes in recent years, particularly in the area of mental retardation and developmental delay,7  but also by uncovering the genetic basis of schizophrenia8  and familial amyotrophic lateral sclerosis,9  as well as by identifying the causal mutation of several hitherto unidentified rare inherited diseases. One of the most promising applications of exome sequencing is led by Evan Eichler group (also at the University of Washington/Howard Hughes Medical Institute) as they have identified several causal gene variants for autism spectrum disorder whose etiology has been enigmatic.10,11  Several university hospitals have begun to offer Clinical Laboratory Improvement Amendments (a federal laboratory standard)–certified clinical exome sequencing and it will be only a matter of time, before we will be confronted with our first patient whose exome has been sequenced and whose exome data are accessible on our electronic medical records. It probably will be our colleagues taking care of children with intellectual disabilities or cancer patients who will be confronted with clinical exome data. What we are going to do with them? What is the impact for the practicing anesthesiologist? At present and given the nearly uniform lack of guidelines on how to interpret clinical exome data, the impact is largely negligible. Over the course of the next years, however, as exome data interpretation will become more automated, one of the first areas of relevance for practicing anesthesiologists that should see an integration of exome data will be genotype-based perioperative drug therapy.

Although clinical integration of exome results is still in the future, at present we can marvel at the scientific breakthroughs exome sequencing has enabled. The two studies in this issue of Anesthesiology,1,2  as well as two earlier reports,12,13  may represent only an incremental knowledge gain in malignant hyperthermia research. What sets them apart is that by using exome sequencing they shepherd our specialty into the era of genomic medicine and therefore they truly represent a milestone. What a wonderful coincidence that one of the studies1  comes from the University of Washington, the very same place where the method of exome sequencing was originally invented.

References

1.
Kim
JH
,
Jarvik
GP
,
Browning
BL
,
Rajagopalan
R
,
Gordon
AS
,
Rieder
MJ
,
Robertson
PD
,
Nickerson
DA
,
Fisher
NA
,
Hopkins
PM
:
Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.
Anesthesiology
2013
;
119
:
1054
65
2.
Gonsalves
SG
,
Ng
D
,
Johnston
JJ
,
Teer
JK
,
Stenson
PD
,
Cooper
DN
,
Mullikin
JC
,
Biesecker
LG
:
Using exome data to identify malignant hyperthermia susceptibility mutations.
Anesthesiology
2013
;
119
:
1043
53
3.
Nagele
P
:
Perioperative genomics.
Best Pract Res Clin Anaesthesiol
2011
;
25
:
549
55
4.
Lander
ES
,
Linton
LM
,
Birren
B
,
Nusbaum
C
,
Zody
MC
,
Baldwin
J
,
Devon
K
,
Dewar
K
,
Doyle
M
,
FitzHugh
W
,
Funke
R
,
Gage
D
,
Harris
K
,
Heaford
A
,
Howland
J
,
Kann
L
,
Lehoczky
J
,
LeVine
R
,
McEwan
P
,
McKernan
K
,
Meldrim
J
,
Mesirov
JP
,
Miranda
C
,
Morris
W
,
Naylor
J
,
Raymond
C
,
Rosetti
M
,
Santos
R
,
Sheridan
A
,
Sougnez
C
,
Stange-Thomann
N
,
Stojanovic
N
,
Subramanian
A
,
Wyman
D
,
Rogers
J
,
Sulston
J
,
Ainscough
R
,
Beck
S
,
Bentley
D
,
Burton
J
,
Clee
C
,
Carter
N
,
Coulson
A
,
Deadman
R
,
Deloukas
P
,
Dunham
A
,
Dunham
I
,
Durbin
R
,
French
L
,
Grafham
D
,
Gregory
S
,
Hubbard
T
,
Humphray
S
,
Hunt
A
,
Jones
M
,
Lloyd
C
,
McMurray
A
,
Matthews
L
,
Mercer
S
,
Milne
S
,
Mullikin
JC
,
Mungall
A
,
Plumb
R
,
Ross
M
,
Shownkeen
R
,
Sims
S
,
Waterston
RH
,
Wilson
RK
,
Hillier
LW
,
McPherson
JD
,
Marra
MA
,
Mardis
ER
,
Fulton
LA
,
Chinwalla
AT
,
Pepin
KH
,
Gish
WR
,
Chissoe
SL
,
Wendl
MC
,
Delehaunty
KD
,
Miner
TL
,
Delehaunty
A
,
Kramer
JB
,
Cook
LL
,
Fulton
RS
,
Johnson
DL
,
Minx
PJ
,
Clifton
SW
,
Hawkins
T
,
Branscomb
E
,
Predki
P
,
Richardson
P
,
Wenning
S
,
Slezak
T
,
Doggett
N
,
Cheng
JF
,
Olsen
A
,
Lucas
S
,
Elkin
C
,
Uberbacher
E
,
Frazier
M
,
Gibbs
RA
,
Muzny
DM
,
Scherer
SE
,
Bouck
JB
,
Sodergren
EJ
,
Worley
KC
,
Rives
CM
,
Gorrell
JH
,
Metzker
ML
,
Naylor
SL
,
Kucherlapati
RS
,
Nelson
DL
,
Weinstock
GM
,
Sakaki
Y
,
Fujiyama
A
,
Hattori
M
,
Yada
T
,
Toyoda
A
,
Itoh
T
,
Kawagoe
C
,
Watanabe
H
,
Totoki
Y
,
Taylor
T
,
Weissenbach
J
,
Heilig
R
,
Saurin
W
,
Artiguenave
F
,
Brottier
P
,
Bruls
T
,
Pelletier
E
,
Robert
C
,
Wincker
P
,
Smith
DR
,
Doucette-Stamm
L
,
Rubenfield
M
,
Weinstock
K
,
Lee
HM
,
Dubois
J
,
Rosenthal
A
,
Platzer
M
,
Nyakatura
G
,
Taudien
S
,
Rump
A
,
Yang
H
,
Yu
J
,
Wang
J
,
Huang
G
,
Gu
J
,
Hood
L
,
Rowen
L
,
Madan
A
,
Qin
S
,
Davis
RW
,
Federspiel
NA
,
Abola
AP
,
Proctor
MJ
,
Myers
RM
,
Schmutz
J
,
Dickson
M
,
Grimwood
J
,
Cox
DR
,
Olson
MV
,
Kaul
R
,
Raymond
C
,
Shimizu
N
,
Kawasaki
K
,
Minoshima
S
,
Evans
GA
,
Athanasiou
M
,
Schultz
R
,
Roe
BA
,
Chen
F
,
Pan
H
,
Ramser
J
,
Lehrach
H
,
Reinhardt
R
,
McCombie
WR
,
de la Bastide
M
,
Dedhia
N
,
Blöcker
H
,
Hornischer
K
,
Nordsiek
G
,
Agarwala
R
,
Aravind
L
,
Bailey
JA
,
Bateman
A
,
Batzoglou
S
,
Birney
E
,
Bork
P
,
Brown
DG
,
Burge
CB
,
Cerutti
L
,
Chen
HC
,
Church
D
,
Clamp
M
,
Copley
RR
,
Doerks
T
,
Eddy
SR
,
Eichler
EE
,
Furey
TS
,
Galagan
J
,
Gilbert
JG
,
Harmon
C
,
Hayashizaki
Y
,
Haussler
D
,
Hermjakob
H
,
Hokamp
K
,
Jang
W
,
Johnson
LS
,
Jones
TA
,
Kasif
S
,
Kaspryzk
A
,
Kennedy
S
,
Kent
WJ
,
Kitts
P
,
Koonin
EV
,
Korf
I
,
Kulp
D
,
Lancet
D
,
Lowe
TM
,
McLysaght
A
,
Mikkelsen
T
,
Moran
JV
,
Mulder
N
,
Pollara
VJ
,
Ponting
CP
,
Schuler
G
,
Schultz
J
,
Slater
G
,
Smit
AF
,
Stupka
E
,
Szustakowski
J
,
Thierry-Mieg
D
,
Thierry-Mieg
J
,
Wagner
L
,
Wallis
J
,
Wheeler
R
,
Williams
A
,
Wolf
YI
,
Wolfe
KH
,
Yang
SP
,
Yeh
RF
,
Collins
F
,
Guyer
MS
,
Peterson
J
,
Felsenfeld
A
,
Wetterstrand
KA
,
Patrinos
A
,
Morgan
MJ
,
de Jong
P
,
Catanese
JJ
,
Osoegawa
K
,
Shizuya
H
,
Choi
S
,
Chen
YJ
,
Szustakowki
J
;
International Human Genome Sequencing Consortium
:
Initial sequencing and analysis of the human genome.
Nature
2001
;
409
:
860
921
5.
Scherer
S
:
A Short Guide to the Human Genome
.
Cold Spring Harbor
,
Cold Spring Harbor Laboratory Press
,
2008
6.
Ng
SB
,
Turner
EH
,
Robertson
PD
,
Flygare
SD
,
Bigham
AW
,
Lee
C
,
Shaffer
T
,
Wong
M
,
Bhattacharjee
A
,
Eichler
EE
,
Bamshad
M
,
Nickerson
DA
,
Shendure
J
:
Targeted capture and massively parallel sequencing of 12 human exomes.
Nature
2009
;
461
:
272
6
7.
Vissers
LE
,
de Ligt
J
,
Gilissen
C
,
Janssen
I
,
Steehouwer
M
,
de Vries
P
,
van Lier
B
,
Arts
P
,
Wieskamp
N
,
del Rosario
M
,
van Bon
BW
,
Hoischen
A
,
de Vries
BB
,
Brunner
HG
,
Veltman
JA
:
A de novo paradigm for mental retardation.
Nat Genet
2010
;
42
:
1109
12
8.
Xu
B
,
Roos
JL
,
Dexheimer
P
,
Boone
B
,
Plummer
B
,
Levy
S
,
Gogos
JA
,
Karayiorgou
M
:
Exome sequencing supports a de novo mutational paradigm for schizophrenia.
Nat Genet
2011
;
43
:
864
8
9.
Johnson
JO
,
Mandrioli
J
,
Benatar
M
,
Abramzon
Y
,
Van Deerlin
VM
,
Trojanowski
JQ
,
Gibbs
JR
,
Brunetti
M
,
Gronka
S
,
Wuu
J
,
Ding
J
,
McCluskey
L
,
Martinez-Lage
M
,
Falcone
D
,
Hernandez
DG
,
Arepalli
S
,
Chong
S
,
Schymick
JC
,
Rothstein
J
,
Landi
F
,
Wang
YD
,
Calvo
A
,
Mora
G
,
Sabatelli
M
,
Monsurrò
MR
,
Battistini
S
,
Salvi
F
,
Spataro
R
,
Sola
P
,
Borghero
G
,
Galassi
G
,
Scholz
SW
,
Taylor
JP
,
Restagno
G
,
Chiò
A
,
Traynor
BJ
;
ITALSGEN Consortium
:
Exome sequencing reveals VCP mutations as a cause of familial ALS.
Neuron
2010
;
68
:
857
64
10.
O’Roak
BJ
,
Deriziotis
P
,
Lee
C
,
Vives
L
,
Schwartz
JJ
,
Girirajan
S
,
Karakoc
E
,
Mackenzie
AP
,
Ng
SB
,
Baker
C
,
Rieder
MJ
,
Nickerson
DA
,
Bernier
R
,
Fisher
SE
,
Shendure
J
,
Eichler
EE
:
Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations.
Nat Genet
2011
;
43
:
585
9
11.
O’Roak
BJ
,
Vives
L
,
Fu
W
,
Egertson
JD
,
Stanaway
IB
,
Phelps
IG
,
Carvill
G
,
Kumar
A
,
Lee
C
,
Ankenman
K
,
Munson
J
,
Hiatt
JB
,
Turner
EH
,
Levy
R
,
O’Day
DR
,
Krumm
N
,
Coe
BP
,
Martin
BK
,
Borenstein
E
,
Nickerson
DA
,
Mefford
HC
,
Doherty
D
,
Akey
JM
,
Bernier
R
,
Eichler
EE
,
Shendure
J
:
Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.
Science
2012
;
338
:
1619
22
12.
Sambuughin
N
,
Liu
X
,
Bijarnia
S
,
Wallace
T
,
Verma
IC
,
Hamilton
S
,
Muldoon
S
,
Tallon
LJ
,
Wang
S
:
Exome sequencing reveals SCO2 mutations in a family presented with fatal infantile hyperthermia.
J Hum Genet
2013
;
58
:
226
8
13.
Böhm
J
,
Leshinsky-Silver
E
,
Vassilopoulos
S
,
Le Gras
S
,
Lerman-Sagie
T
,
Ginzberg
M
,
Jost
B
,
Lev
D
,
Laporte
J
:
Samaritan myopathy, an ultimately benign congenital myopathy, is caused by a RYR1 mutation.
Acta Neuropathol
2012
;
124
:
575
81